In this study, we demonstrated that Hyperoside effectively blocks PANoptosis pathway activation by inhibiting AKT1 phosphorylation in podocytes, thereby protecting glomerular cells in both in vivo and in vitro LN models. Here, AKT1 is linked to lobular neoplasia.